Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK6 | Q16659 | 12/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17435333 | 1.00 | MAPK6 (0.45) | MAPK6GSK3BGSK3AWNT1DYRK1A | |
| SCHEMBL16013127 | 0.89 | MAPK6 (0.46) | MAPK6GSK3BGSK3ACCNKCDK12 | |
| SCHEMBL16013128 | 0.89 | MAPK6 (0.46) | MAPK6GSK3BGSK3ACCNKCDK12 | |
| SCHEMBL16012202 | 0.88 | MAPK6 (0.43) | MAPK6GSK3BGSK3ACCNKCDK12 | |
| SCHEMBL17435273 | 0.88 | MAPK6 (0.43) | MAPK6GSK3BGSK3ACCNKCDK12 | |
| SCHEMBL16012196 | 0.88 | MAPK6 (0.60) | MAPK6GSK3BGSK3ACCNKCDK12 | |
| SCHEMBL16012197 | 0.88 | MAPK6 (0.60) | MAPK6GSK3BGSK3ACCNKCDK12 | |
| SCHEMBL16022114 | 0.87 | GPR119 (0.45) | MAPK6GSK3BGSK3A | |
| SCHEMBL16014928 | 0.84 | EIF2AK4 (0.47) | MAPK6GSK3BGSK3A | |
| SCHEMBL16012952 | 0.84 | MAPK6 (0.44) | MAPK6GSK3BGSK3ACCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | claimed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | claimed |
| EP-2964649-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | claimed |
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | claimed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2964649-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | EIF2AK4, GCN1, GTF2I | MAPK6 2535/4885GSK3B 2810/4885GSK3A 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.